Press release content from Globe Newswire. The AP news staff was not involved in its creation.
UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 .
Sumitovant BiopharmaJanuary 26, 2021 GMT
NEW YORK, LONDON,, Jan. 26, 2021 (GLOBE NEWSWIRE) Sumitovant Biopharma Ltd., a majority shareholder of Myovant Sciences (NYSE: MYOV), announced today that Myovant Sciences’ Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain over one year (52 weeks) with minimal and stable bone mineral density loss. The dat a are consistent with the efficacy and safety profile observed through 24 weeks in the Phase 3 SPIRIT 1 and SPIRIT 2 studies. These results will be included in the New Drug Application to the U
UpdatedThu, Jan 28, 2021 at 2:21 pm ET
Replies(32)
Under an archaic Michigan law, Tammy and Jordan Myers must adopt their biological twins born earlier this month to a gestational surrogate, who offered to help the couple for altruistic reasons and who hasn t made a legal claim on the babies. (Shutterstock)
GRAND RAPIDS, MI A decades-old anti-surrogacy law that hasn t kept pace with advances in fertility treatment means a Michigan couple will have to go through the expensive and time-consuming process of adopting their 2-week-old biological twins.
No one doubts that Jordan and Tammy Myers are the biological parents of Eames Alexander and Ellison Erin Jewel Myers, born Jan. 11 at Helen DeVos Children s Hospital in Grand Rapids, Michigan.
Date Time
Share
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
82.8% average reduction from baseline on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain) over one year
Bone mineral density loss was minimal at Week 24 and remained stable through one year
Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021
BASEL, Switzerland and NEW YORK, January 26, 2021 – Myovant Sciences (NYSE: MYOV) and Pfizer Inc. (NYSE: PFE) today announced that the Phase 3 SPIRIT long-term extension study of the investigational once-daily relugolix combination therapy (relugolix 40 mg plus estradiol 1.0 mg and norethindrone acetate 0.5 mg) in women with endometriosis repo
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study .
Myovant Sciences, Inc.January 26, 2021 GMT
84.8% and 73.3% of women reported clinically meaningful reductions in dysmenorrhea (menstrual pain) and non-menstrual pelvic pain at one year
82.8% average reduction from baseline
on the Numerical Rating Scale for dysmenorrhea from 7.4 (severe pain) to 1.3 (mild pain)
over one year
Bone mineral density loss was minimal at Week 24 and remained stable through one year
Data to be included in New Drug Application submission to U.S. Food and Drug Administration anticipated in first half of 2021